Bristol Myers Squibb scores FDA priority review for Opdivo in advanced hodgkin lymphoma
The FDA aims to make a decision by April 8, 2026
The FDA aims to make a decision by April 8, 2026
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m.
Subscribe To Our Newsletter & Stay Updated